BIOA BIOAGE LABS INC.

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.

TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health care industry.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel, structurally differentiated APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts

PR: Chris Patil,

IR: Dov Goldstein,

Partnering:

Web:



EN
20/02/2025

Underlying

BIOABIOAGE LABS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOAGE LABS INC.

 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-...

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced advances in its a...

June 3, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs completes IND-enabling studies for BGE-102, a potent, oral...

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonistsInternally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing EMERYVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinic...

May 29, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs to Present at Upcoming Investor Conferences EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–5, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. •...

May 27, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Reports First Quarter 2025 Financial Results and Provides ...

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic dise...

May 6, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Reports Full Year 2024 Financial Results and Provides Busi...

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candida...

March 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch